Karen Cheng

Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study

Josep Tabernero, Paulo M. Hoff, Lin Shen et al. · The Lancet Oncology · 2018 · 468 citations

Surgical Oncology, Her2-positive Metastatic Gastric, Placebo-controlled Phase 3 +8

Pharmacokinetics and safety of aztreonam/avibactam for the treatment of complicated intra-abdominal infections in hospitalized adults: results from the REJUVENATE study

Oliver A. Cornely, José Miguel Cisneros, Julián Torre‐Cisneros et al. · Journal of Antimicrobial Chemotherapy · 2019 · 115 citations · Full text

Pandrug-resistant Pseudomonas aeruginosa among hospitalised patients: clinical features, risk-factors and outcomes

Chung‐Yi Wang, Jih‐Shuin Jerng, Karen Cheng et al. · Clinical Microbiology and Infection · 2006 · 101 citations · Full text

Antimicrobial Susceptibility, Healthcare-associated Infection, Clinical Features +10

Safety and Efficacy of Ceftazidime–Avibactam in the Treatment of Children ≥3 Months to <18 Years With Complicated Urinary Tract Infection: Results from a Phase 2 Randomized, Controlled Trial

John S. Bradley, Emmanuel Roilides, Helen Broadhurst et al. · The Pediatric Infectious Disease Journal · 2019 · 68 citations · Full text

Safety and Efficacy of Ceftazidime-Avibactam Plus Metronidazole in the Treatment of Children ≥3 Months to <18 Years With Complicated Intra-Abdominal Infection: Results From a Phase 2, Randomized, Controlled Trial

John S. Bradley, Helen Broadhurst, Karen Cheng et al. · The Pediatric Infectious Disease Journal · 2019 · 66 citations · Full text